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Abstract.
Background andObjective: Mild cognitive impairment (MCI) patients with small vessel disease (SVD) are at high dementia
risk. We tested the effects of cognitive rehabilitation in these patients using the Attention Process Training-II (APT-II) program
in a single-blinded, randomized clinical trial.
Methods: Patients were randomized to APT-II or standard care and evaluated at baseline, 6, and 12 months with functional,
quality of life, cognitive tests, and resting state functional MRI (rsfMRI).
Results: Forty-six patients were enrolled and 43 (mean ± SD age 75.1 ± 6.8) completed the study. No change was seen
in functionality and quality of life between treated and non-treated patients. However, the Rey Auditory-Verbal Learning
Test immediate recall showed a significant improvement in treated compared to non-treated group (change score 6 versus
12 months: 1.8 ± 4.9 and –1.4 ± 3.8, p = 0.021; baseline versus 12 months: 3.8 ± 6.1 and 0.2 ± 4.4, p = 0.032). A higher
proportion of treated patients had stable/better evaluation compared to non-treated group on Visual search test (6 versus
12 months: 95% versus 71%, p = 0.038) and Rey–Osterrieth Complex Figure copy (6 versus 12 months: 95% versus 67%,
p = 0.027). RsfMRI, performed in a subsample, showed that the difference between follow-up and baseline in synchronization
of activity in cerebellar areas was significantly greater in treated than in non-treated patients.
Conclusion: We were unable to show a significant effect in quality of life or functional status in treated patients with MCI
and SVD. However, APT-II produces some beneficial effects in focused attention and working memory and seems to increase
activity in brain circuits involved in cognitive processes.
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INTRODUCTION
Cerebral small vessel disease (SVD) is a leading
cause of cognitive impairment [1–3]. Patients with
SVD and mild cognitive impairment (MCI) are at
high risk of transition to dementia [4]. Therapeutic
approaches to reduce this risk are scanty and no drug
is approved to obstacle this transition. Cognitive reha-
bilitation or training may therefore be options in this
regard.
The Attention Process Training-II (APT-II) pro-
gram consists of a group of hierarchically organized
tasks aimed at exercising different components of
attention (focused, sustained, selective, alternating,
and divided) [5]. Because the APT-II contains specific
exercises to facilitate generalization to daily life, the
skills learned during the training are expected to gen-
eralize to daily activities and thus ameliorate patient’s
overall quality of life.
In this study, we aimed at investigating: 1) the
effectiveness of the APT-II program on the rehabili-
tation of attention in patients with MCI with SVD; 2)
the effect of the possible cognitive improvement in
real life, in terms of functionality in daily activities
and quality of life; 3) the possible impact of the atten-
tion training on brain activity evaluated with resting
state functional MRI (rsfMRI).
MATERIALS AND METHODS
The RehAtt (Rehabilitation of Attention) study
is a 3-year prospective, single-blinded, randomized
clinical trial. Its rationale and methodology were
extensively reported elsewhere [6]. Methodological
details concerning sample size justification, method
of randomization, and interventions are detailed in
the Supplementary Material.
The study was conducted in accordance with
the Helsinki Declaration and was approved by the
local ethics committee; each patient gave a written
informed consent. The study is registered in the Clin-
icalTrials.gov registry (identifier number: NCT0203
3850).
Included patients were diagnosed as affected by
MCI, with an attentional deficit, and SVD according
to the following criteria: 1) MCI according to Win-
blad et al.’s criteria [7] and operationalized according
to Salvadori et al. [8]; 2) evidence of impairment
across attention neuropsychological tests (i.e., at
least one score borderline among attention/executive
functions tests); 3) evidence on MRI of moderate
to severe age-related white matter hyperintensities
(WMH) according to a modified Fazekas scale [9].
The degree of WMH severity was rated on Fluid
Attenuated Inversion Recovery (FLAIR) sequences,
taking into account only deep and subcortical white
matter lesions. The modified Fazekas scale is a visual
scale based on a categorization into 3 severity classes:
grade 1 (mild WMH) = single lesions below 10 mm,
areas of ‘grouped’ lesions smaller than 20 mm in any
diameter; grade 2 (moderate WMH) = single lesions
between 10 and 20 mm, areas of ‘grouped’ lesions
more than 20 mm in any diameter, no more than ‘con-
necting bridges’ between individual lesions; grade 3
(severe WMH) = single lesions or confluent areas of
hyperintensity 20 mm or more in any diameter. Exclu-
sion criteria were: 1) inability or refusal to undergo
brain MRI; 2) inability to give an informed consent;
3) age <18 y.
At baseline, according to the study protocol [6],
each patient underwent an extensive clinical, func-
tional, and neuropsychological assessment and an
MRI examination. The neuropsychological evalu-
ation was carried out using the VMCI-Tuscany
neuropsychological battery [10].
After baseline assessment, participants were ran-
domly assigned to the intervention group (attention
training) or the control group (standard care), accord-
ing to a stratified randomization (see Supplementary
Material) [6].
Participants in the intervention group were
scheduled to receive a total of 40 h (2-h weekly ses-
sions for 20 weeks) of individual cognitive training
by means of the APT-II program. All cognitive
training sessions were administered by a clinical neu-
ropsychologist. Participants in the control group did
not receive cognitive interventions, were instructed
to have a usual lifestyle, and were provided of med-
ication and clinic consultations as usually needed
(see Supplementary Material for details on interven-
tions).
The study protocol comprises follow-up visits at 6
and 12 months. At the follow-up visits, clinical, func-
tional, and neuropsychological assessment were the
same of the baseline protocol. The MRI assessment
was repeated at 1-year follow-up. The neurologist
who collected clinical, functional and neuropsycho-
logical data was blind to the intervention conditions.
Participants could not be kept blind to the interven-
tion conditions, but they were asked not to reveal
their group membership during follow-up assess-
ments, and the neurologist remained blind to training
allocation for the entire study duration.
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MRI examination protocol, rsfMRI data pre-
processing, regional homogeneity (ReHo) maps
computation, and statistical analysis of rsfMRI data
are detailed in the Supplementary Material.
Outcome measures
Primary outcomes
The primary outcomes were the improvement of
functionality in activities of daily living and quality
of life in treated compared to non-treated patients.
Since this was a pilot study, we decided to assess
each outcome with more than one scale.
Functional status was measured by means of three
scales administered to the caregiver:
• Activities of Daily Living scale (ADL); score
range 0–6 (higher scores represent less disabil-
ity) [11].
• Instrumental Activities of Daily Living scale
(IADL); score range 0–8 (higher scores repre-
sent more disability) [12].
• Disability Assessment in Dementia scale; total
score in percentage (higher scores represent less
disability) [13].
Quality of life was measured by means of four
questionnaires on perceived health and/or cognitive
status administered to the patient:
• Short Form Health Survey (SF-36); 2 summary
scores (Physical and Mental Component Sum-
mary) on a 0–100 scale (higher scores represent
less disability) [14].
• EuroQol; single summary index and visual ana-
logue 0–100 scale (higher scores represent better
health status) [15].
• Attention Questionnaire; score range 0–36
(higher scores represent more presence of atten-
tion problems) [5].
• Geriatric Depression Scale; score range 0–15
(higher scores represent more presence of
depressive symptoms) [16].
All the functional and quality of life scales are
detailed in the Supplementary Material.
Secondary outcomes
Secondary outcomes included:
1) Improvement in cognitive performance in any
of 14 scores deriving from the 11 neuropsy-
chological tests included in the VMCI-Tuscany
neuropsychological battery [10], detailed in
the Supplementary Material. Cognitive per-
formance of each patient was classified as
‘normal’, ‘borderline’ (an age- and education-
adjusted score between the outer and inner
confidence limits for the 5th centile of the nor-
mal population), or ‘abnormal’ (an age- and
education-adjusted score below the outer con-
fidence limit for the 5th centile of the normal
population).
2) Reduction of the risk of transition to demen-
tia. Data collected during the 1-year follow-up
visit were used to evaluate the occurrence of a
transition from MCI to dementia according to
DSM-V criteria [17].
3) Improvement in long-term brain activity as
measured by means of ReHo of rsfMRI data,
as a result of a training-induced cognitive plas-
ticity, evaluated six months after the end of the
cognitive rehabilitation period (see Supplemen-
tary Material for further details).
Statistical analysis
Descriptive analyses were used to illustrate the
baseline total sample characteristics. To verify if the
attention training and standard care groups differed
in baseline characteristics other than those included
in the stratified randomization, independent sample t
tests and chi square tests were used to compare demo-
graphics, vascular risk factors, and global cognitive
and functional status.
Primary outcomes and cognitive secondary out-
comes were analyzed according to two different
approaches:
• Changes in scores () approach. Delta scores
(s) were calculated by computing the dif-
ference between the scores obtained in two
evaluations (baseline versus 6 months; 6 versus
12 months; baseline versus 12 months) for each
patient. All s were calculated in order that a
positive score indicates an improvement, while
a negative score indicates a worsening. Delta
scores were analyzed using independent sample
t tests with treatment (attention training versus
standard care) as the only independent variable.
• Clinically signiﬁcance approach. The avail-
ability of t scores for the SF-36 Physical and
Mental Component Summary scores allowed us
to classify each patient evaluation as ‘normal
well-being’ (t score >40) or ‘reduced well-
being’ (t score ≤40) at each visit. As previously
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detailed in the secondary outcomes section,
the availability of national norms for the cog-
nitive variables allowed us to classify each
patient’s performance as ‘normal’, ‘borderline’,
or ‘abnormal’ at each visit. Variations in per-
formance categories over time (baseline versus
6 month; 6 versus 12 month; baseline versus
12 month) were evaluated for each patient and
dichotomized as: ‘stable or better evaluation’ or
‘worse evaluation’. Variations in performance
categories were analyzed using chi square tests.
For the analyses on primary and cognitive sec-
ondary outcomes, effect sizes were estimated by
means of the unbiased Hedges’ g (a variation of
Cohen’s d corrected for biases due to small sam-
ple sizes) for the independent sample t tests, and by
means of the Phi coefficient (ϕ) for the chi square
tests.
Chi square test for a 2 × 2 contingency table was
used to compare patients who became demented at
1-year follow-up visit with those who did not, in the
two treatment groups.
Statistical analysis of rsfMRI data was carried
out by feeding Z-transformed ReHo data into voxel-
wise inter-subject statistics using permutation-based
nonparametric inference (randomize, also part of
FSL) within the general linear model (GLM) frame-
work. Specifically, to evaluate the possible effect of
the treatment, we performed a voxel-wise between-
group comparison of the difference between the
ReHo at follow-up and baseline between treated and
non-treated patients (see Supplementary Material for
further details).
RESULTS
The enrolment started on October 1, 2013 and was
completed on April 30, 2015. To reach the foreseen
number of 40 patients, we evaluated 175 potentially
eligible patients. Of these, 129 (74%) were excluded.
As shown in Fig. 1, main reasons for non-enrolment
Fig. 1. Flow diagram showing patients’ attrition from the screening phase to follow-up assessments.
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Table 1
Total sample characteristics and comparisons between attention training and standard care groups at baseline
Total sample Attention training Standard care p
Score range n = 43 n = 21 n = 22
Age, y (mean ± SD) – 75.1 ± 6.8 74.2 ± 6 75.9 ± 7.6 0.417∗
Education, y – 8.2 ± 4.3 9 ± 5.3 7.4 ± 3 0.232∗
Sex (% males) – 65% (n = 28) 62% (n = 13) 68% (n = 15) 0.666#
Hypertension – 88% (n = 38) 86% (n = 18) 91% (n = 20) 0.595#
Hypercholesterolemia – 72% (n = 31) 76% (n = 16) 68% (n = 15) 0.558#
Diabetes – 16% (n = 7) 14% (n = 3) 18% (n = 4) 0.729#
Smoking habits – 42% (n = 18) 52% (n = 11) 32% (n = 7) 0.172#
History of stroke – 40% (n = 17) 33% (n = 7) 45% (n = 10) 0.416#
Alcohol consumption – 44% (n = 19) 43% (n = 9) 45% (n = 10) 0.864#
Mini Mental State Examination 0–30 26.4 ± 3 27.1 ± 2.6 25.7 ± 3.2 0.132∗
Montreal Cognitive Assessment 0–30 19.2 ± 4.6 19.9 ± 4.8 18.6 ± 4.4 0.360∗
Activities of Daily Living (preserved items) 0–6 5.9 ± 0.4 5.9 ± 0.3 5.9 ± 0.4 0.970∗
Instrumental Activities of Daily Living (impaired items) 0–8 2.1 ± 2.2 1.9 ± 2.1 2.2 ± 2.4 0.639∗
Disability Assessment in Dementia 0–100 88 ± 15.5 91.9 ± 11.9 84.2 ± 17.8 0.101∗
Attention Questionnaire 0–36 15.5 ± 9.9 15.1 ± 11.5 15.9 ± 8.5 0.793∗
EuroQol (summary index) –1/+1 0.7 ± 0.3 0.7 ± 0.3 0.7 ± 0.3 0.491∗
EuroQol (visual scale) 0–100 65.2 ± 17.8 63.1 ± 18.3 67.3 ± 17.5 0.449∗
Geriatric Depression Scale 0–15 4.8 ± 3.8 4.6 ± 4 4.9 ± 3.8 0.748∗
∗Independent sample t tests. #Chi square tests.
were: refusal (n = 45), not fitting the cognitive criteria
(n = 28 normal, n = 15 demented), contraindications
for the MRI examination (n = 20), not fitting the MRI
criteria (n = 15). Forty-six patients (26%) were finally
enrolled and thoroughly assessed according to the
study protocol.
Out of the 46 enrolled patients, 1 dropped-out
before randomization because of cerebral hemor-
rhage, and 2 dropped-out after the allocation to the
treatment group: one after a total of 4 h for a gastroin-
testinal perforation that required emergency surgery
and a long hospitalization, while another interrupted
the treatment after 30 h and refused to undergo the
6-month follow-up; he consented to be contacted for
the 12-month follow-up visit but deceased before due
to a metastatic liver cancer (Fig. 1).
The final RehAtt cohort includes 43 patients
affected by MCI with SVD; 22 were randomized to
the standard care group and 21 to the attention train-
ing group. All these patients completed the protocol,
were reassessed at 6 and 12 months, and repeated the
MRI exams (Fig. 1).
As shown in Table 1, 65% (n = 28) of the total
basal sample were males, and the mean (±SD) age
and years of education were 75.1 ± 6.8 and 8.2 ± 4.3,
respectively. The vascular risk factors distribution
and the cognitive and functional tests profiles were
those expected in a sample of MCI with SVD
(Table 1). No patient was on antidementia drugs
before or during the trial. Comparisons between
attention training and standard care groups showed
that there were not statistically significant differences
in baseline demographics, vascular risk factors, and
global cognitive and functional status (Table 1).
Results for the primary functional outcomes are
shown in Table 2. Considering both the s and the
clinically significance approaches, treated and non-
treated patients did not differ significantly in any of
the functional or quality of life measures after 6 or 12
months.
Results for the cognitive secondary outcomes are
shown in Table 3. Using the s approach, we found
a statistically significant difference between treated
and non-treated patients in the Rey Auditory-Verbal
Learning Test immediate recall (working memory)
when comparing 6 versus 12 months (effect size:
Hedges’ g = 0.72) and baseline versus 12 months
(effect size: Hedges’ g = 0.67) in favor of treated
patients. Taking into consideration the clinically sig-
nificance approach, we found that percentages of
patients having a stable or better evaluation were
significantly higher in treated patients compared to
non-treated ones both in the Visual search test (effect
size: ϕ = 0.32) and in the Rey–Osterrieth Complex
Figure immediate copy (effect size: ϕ = 0.34) in the 6
versus 12 months’ comparison.
Out of the 43 enrolled patients, 3/21 (14%) in
the treatment group and 5/22 (23%) in the standard
care group were diagnosed as demented at 1-year
follow-up, 17/21 treated (81%) and 17/22 non-treated
(77%) remained MCI, and 1 treated patient reverted
to normal cognitive function. The chi square test
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for the association between treatment and dementia
diagnosis was not statistically significant.
RsfMRI data were available in 22 patients (12
treated and 10 non-treated) after the exclusion of
patients for technical reasons or head movement (in
terms of mean voxel absolute displacement) greater
than 2 mm, and patients with incidental non-lacunar
infarcts in the cerebral cortex, cerebellum, or brain-
stem to avoid a possible confounding effect on
rsfMRI analysis.
In the attention training group, the difference of
Z-transformed ReHo data between follow-up and
baseline was significantly greater than in the standard
care group in 3 clusters whose maximal statistic was
in the vermis VIIIb and in the bilateral VIIb lobule
of cerebellum, respectively (Supplementary Table 1
and Fig. 2). In each cluster, the mean of the difference
of the Z-transformed ReHo (follow-up – baseline)
was positive for the attention training group (ReHo
increased over time) and negative for the standard
care group (ReHo decreased over time) (Fig. 2).
DISCUSSION
RehAtt is the first-ever randomized clinical trial
using cognitive training to improve functional out-
come and cognitive performances of patients with
MCI and SVD.
We were not able to detect a favorable effect of
the APT-II program on functional status and quality
of life in our elderly sample. We observed instead
some moderately beneficial effects with medium to
large effect sizes on a few cognitive tests evaluating
attention and working memory domains. Moreover,
APT-II program also produced an increased activity
in brain circuits involved in cognitive processes.
Overall, the trial has, therefore, to be consid-
ered inconclusive. The main possible reason for this
could be obviously treatment inefficacy. One could
alternatively hypothesize that the trial could be under-
powered due to the limited sample size, and therefore
effects on quality of life and activities of daily liv-
ing were hard to detect. Also, treatment duration and
intensity may have played a role. It is not known
whether the same program implemented for longer
periods or a more intensive treatment could have
produced different effects. More intensive treatments
however generate compliance issues.
Notably, in our study, the non-treated group
remained globally stable in functional and cogni-
tive performances. This behavior appears different
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Fig. 2. Improvement in long-term brain activity measured by ReHo of rsfMRI data. Between-group voxel-wise map (TFCE) showing
significant (p < 0.05, corrected) evidence for a greater Z-transformed ReHo difference (12 months – baseline) in cerebellar areas (vermis
VIIIb and bilateral VIIb lobule) involved in cognitive processes in the attention training group as compared to standard care group. The map
is overlaid on the MNI152 template. In each cluster, the mean of the difference of the Z-transformed ReHo was positive for the attention
training group (ReHo increased over time) and negative for the standard care group (ReHo decreased over time).
from the natural history of MCI patients with SVD in
whom a decline is usually seen. This behavior of the
control group might have attenuated the differences
between treated and non-treated patients. Interest-
ingly, this behavior of the placebo groups has been
seen also in other trials in similar patients [18].
One last point concerns the mean age of our pop-
ulation, that is quite old, and the choice to include
patients with a moderate to severe degree of WMH.
Whether the same approach could have different
effect either in younger age-groups of patients or in
a population with a lesser burden of WMH remains
to be explored.
A few considerations related to this type of cogni-
tive treatment can be made. First, the APT-II program
is demanding in terms of patient compliance. This
notwithstanding, the rate of drop-out was extremely
low in our study. However, these cognitive training
approaches can be proposed only to well-motivated
patients and as reflected by the high selection rate
recorded in our study in which a not negligible
number of patients refused to take part.
Finally, as typical of cognitive training approaches,
the APT-II program places increasing demands on
working memory systems and complex attentional
control. The lack of efficacy of treatment in our
study may also depend on the fact that a direct
attention cognitive training could be a challenging
approach for elderly MCI patients, thus reducing
the possibility to achieve a generalizable effect. In
our elderly cohort, it could be hypothesized that
our attention training program could have produced
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some potentially beneficial effects only on those tests
whose performance is influenced by basic attentional
control underlying working memory. Future trials
on elderly MCI patients should verify the efficacy
of cognitive interventions that are less demanding
and more closely related to everyday life tasks,
such as cognitive rehabilitation approaches based on
meta-cognitive strategies’ learning.
Despite the null effect on primary outcomes,
the APT-II treatment induced beneficial, although
preliminary, effects on some cognitive measures.
Moreover, it was associated with a greater difference
between follow-up and baseline in the synchroniza-
tion of activity of some cerebellar areas. This change
of cerebellar activity involved the vermis VIIIb and
the VIIb lobule, bilaterally. These cerebellar regions
are among those known to have projections from and
to the prefrontal cortex (cerebello-thalamo-cortical
loop) and considered crucial for the contribution
of the cerebellum to cognition [19, 20]. Functional
topography of the cerebellum indicates that the left
VIIb lobule is activated during executive function
tasks [21] while VIIb and VIII lobules supports
working memory processes [22]. Since executive
functional tasks also activate several areas located
throughout the cerebellum, with no clear lateraliza-
tion or lobular pattern [21], and taking into account
that neuroplasticity phenomena associated with SVD
can imply variable rearrangement (expansion and
dislocation) of functional areas [23], we hypothe-
size that the above ReHo differences may reflect
possible compensatory phenomena induced by the
treatment. The increased activity in VIIb and VIII
lobules in treated patients appears also in line with
the improvement in one working memory task. How-
ever, these rsfMRI results need to be taken with
caution considering the high drop-out rate on this
examination.
The above rsfMRI finding, although preliminary,
is in agreement with the involvement of cerebellum in
the pathophysiology of cognitive deficits in patients
with MCI and SVD revealed by ReHo analysis of
rsfMRI data [24].
Of note, these increases in brain activity and
improvement in cognitive testing were sustained
because they were detected 6 months after the cessa-
tion of the cognitive program. Taken together, these
data on secondary outcomes seem to outline that
the cognitive treatment with the APT-II program has
some potential effects whose clinical significance in
terms of functionality and quality of life is poorly
defined.
Limitations of our study need to be considered. The
limited sample size and the lack of a priori power
analysis partially attenuated the statistical validity
of our preliminary results that will have to be fur-
ther investigated in future confirmatory trials planned
according to effect sizes derived from the present
study.
Another possible limitation may be the lack of
evaluation of markers of Alzheimer’s disease (cere-
brospinal fluid biomarkers or positron emission
tomography) to better define the etiology of our
sample, and rule out the degenerative component.
Nevertheless, this patient sample represents what is
frequently encountered in clinical practice, and the
study was designed to offer therapeutic options that
could be easily implemented in a real-world clin-
ical setting without requiring advanced diagnostic
techniques not easily available.
In conclusion, the APT-II program could have the
potential to produce some beneficial effects on cogni-
tive status and brain activity in patients with MCI and
SVD. However, the RehAtt study has been conceived
and designed as a pilot study, and our preliminary
results primarily represent a methodological back-
ground for the development of other clinical trials in
larger patient cohorts.
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